1st International Conference on Screening for Lung Cancer Weill Medical College of Cornell University October 1-3, 1999

Friday, October 1st, 1999		
Morning Plenary Session Location: Uris Auditorium		
8:30-8:45	Mission of the conference - Robert Smith, american Cancer Society and James P. Smith, Weill Medical College of Cornell University	
8:45-8:55	Perspective of the at-risk person - Margaret McCarthy, alliance for Lung Cancer Advocacy, support, and Education	
Morning Session: Moderator - William Travis, Armed Forces Institute of Pathology		
8:55 - 9:20	CXR-detected stage I lung cancer - How curable is it and is there "over- diagnosis" - Darryl Carter, Yale School of Medicine and James Fett, Mayo Clinic.	
9:20-9:30	Discussion	
9:30-9:45	CT-detected stage I lung cancer - Criteria for pathologic diagnosis, and frequency of questionable cases - Masayuki Noguchi, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki, Japan	
9:45 - 10:00	CT-detected stage I lung cancer - How curable is it and is there "over- diagnosis" - Tomotaka Sobue, National Cancer Center Research Institute, Tokyo, Japan	
10:00 - 10:15	CT documentation of growth: techniques, accuracy, applicability - David Yankelevitz, Weill Medical College of Cornell University	
10:15-10:30	Discussion	
10:30-11:00	Coffee Break	
11:00 - 12:00	Panel Discussion - Moderator: William Travis Is Stage I lung cancer curable? Is there "over-diagnosis" of Stage I CXR-detected lung cancer? Is there "over- diagnosis" of Stage I CT-detected lung cancer? To what extent is "overdiagnosis" of the smallest Stage I lung cancers avoidable by combining pathology and CT-documented growth?	
12:00 - 1:30	Lunch	

Afternoon Plenary Session Location: Uris Auditorium		
1:30 - 2:30	Screening for early lung cancer - Moderator: Michael Unger, Fox Chase Cancer Center	
(10 minutes)	Imaging - Claudia Henschke, Weill Medical College of Cornell University	
(10 minutes)	CT and sputum cell: complementary approaches to screening - Melvyn Tockman, H. Lee Moffitt Cancer Center	
(10 minutes)	Research approaches to the management of screen-identified small volume lung cancers - James Mulshine, National Institute of Health	
(10 minutes)	A combined approach of CT and sputum cytology - Kenji Euguchi, National Skikoku Cancer Center Hospital, Matsuyama, Japan	
(10 minutes)	Biomarkers - Adi Gazdar, University of Texas SW Medical Center	
(10 minutes)	Molecular and epidemiological assessment of individuals at risk of developing lung cancer - John F. Fields, Roy Castle International Centre for Lung Cancer Research	
Panel Discussion		
2:30 - 3:30	Diagnostic workup of screening positives: Attainable performance	
(10 minutes)	Japanese perspective: National Cancer Center Hospital - Masahiro Kaneko, National Cancer Center Hospital, Tokyo, Japan	
(10 minutes)	Japanese perspective: Community perspective using mobile CT - Shusuke Sone, Shinsu University School of Medicine, Nagano, Japan	
(10 minutes)	H. Lee Moffitt Cancer Center perspective - Robert Clark	
(10 minutes)	Mayo Clinic perspective - Thomas Hartman	
(10 minutes)	Israeli perspective - Dorith Shaham, Jerusalem, Israel	
(10 minutes)	New York perspective - Claudia Henschke	
3:30 - 4:00	Coffee Break	
4:00 - 5:00	Evaluation of Screening - Moderator: Alvin Mushlin, Department of Public Health, Weill Medical College of Cornell University The issues, possible approaches, and relative merits - Presentations and panel discussion Christine Berg, National Cancer Institute Olli S. Miettinen, Epidemiology, McGill University Barry W. Brown, Biostatistics, MD Anderson Marek Kimmel, Statistics, Rice University James Hanley, Statistics, McGill University	

Saturday, October 2nd, 1999		
Subgroup Sessions Location: Weill Auditorium, 2nd floor		
9:00 - 12:00	Subgroup sessions	
12:00 - 1:30	Lunch	
1:30 - 5:00	Subgroup sessions	
Sunday, October 3rd, 1999		
Plenary Session Location: Weill Auditorium, 2nd floor		
9:00 - 12:00	Reports of subgroup sessions	
12:00 - 1:00	Lunch	
1:00 - 4:00	Further discussion and the development of consensus statement about: 1. Are institutional recommendations against lung cancer screening still justifiable? 2. Possible screening regimes for lung cancer screening today? 3. Possible approaches to evaluation of screening regimens? 4. Possible pathologic criteria for early lung cancer?	